Other Antidepressants

Preskorn, Sheldon; Ross, Ruth

doi:10.1007/978-3-642-18500-7_10

Cited by 6 publications

(4 citation statements)

References 202 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27) Individual discrepancies in non-responders may be due to variation in the disposition of ECTP and metabolites as well as the complex nature of MDD. With regard to ECTP concentrations and clinical improvement, our findings are consistent with previous investigations 28,29) even though our sample size was relatively small. Because no other researchers have used a similar metabolomics approach, no comparable data on specific metabolic profiles and treatment response are available in the literature.…”

Section: Resultssupporting

confidence: 92%

Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression

Bandu

Lee

et al. 2023

Mass Spectrometry

View full text Add to dashboard Cite

Liquid chromatography/electrospray ionization-mass spectrometry revealed plasma metabolic profiles for the antidepressant drug escitalopram (ECTP) and associated clinical responses in subjects with major depressive disorder (MDD). Metabolic profiles contribute to variations in responses to drug treatment of depression. To assess clinical responses and treatment outcomes, we quantified the levels of metabolites, including those of the parent drug, in plasma samples collected at different time points (days 0, 7, 14, and 42) during treatment of seven patients with MDD. Results showed that mean plasma levels of key metabolites and ECTP at day 7 were significantly associated with the clinical response at 42 days after treatment. Statistical analyses, including principal component analysis, of key metabolites and ECTP samples at different time points clearly distinguished the clinical responders from non-responder subjects. Although further validation with a larger cohort is necessary, our results indicate that early improvement and plasma levels of key metabolites and ECTP are predictive of therapeutic treatment outcomes and thus can be used to guide the use of ECTP.

show abstract

Section: Resultssupporting

confidence: 92%

Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression

Bandu

Lee

et al. 2023

Mass Spectrometry

View full text Add to dashboard Cite

show abstract

“…132 SSRIs are currently employed to cure mental illnesses because they prevent the uptake of 5-HT, which increases levels of 5-HT inside synaptic cle. 133,134 A novel category of antidepressants with therapeutic potential may be produced by combining SR inhibition mostly with modication of 5HT activity through NK1 antagonist. [135][136][137] Risatti et al reported the optimal a-arylation process which involves the formation of lithium enolate 153 using lithium dicyclohexyl amide accompanied via palladium with 154 utilizing tri-tert-butyl phosphonium tetra-uoroborate as a ligand to provide ester 155, That was then reduced using lithium aluminum hydride to generate alcohol 156 in yields of 77%.…”

Section: Palladium Catalyzed Reactionsmentioning

confidence: 99%

Synthesis of anti-depressant molecules via metal-catalyzed reactions: a review

Kanwal,

Afzal,

Zubair

et al. 2024

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…Currently, widely prescribed types include selective serotonin reuptake inhibitors (SSRIs) and serotoninnorepinephrine reuptake inhibitors (SNRIs) [13][14]. SSRIs are the most commonly prescribed anti-depressants globally while SNRIs may offer advantages over other anti-depressants due to their balanced dual inhibition of monoamine reuptake [15,16].…”

Section: Introductionmentioning

confidence: 99%

Assessment of Reported Adverse Events on Anti-Depressants

Lin

2024

J Drug Addi Ther

View full text Add to dashboard Cite

A mental disorder is characterized by a clinically significant disturbance in an individual’s cognition, emotional regulation, or behavior. One in every eight people around the world was living with a mental disorder in 2019, with depression and anxiety the most common. Currently, popular prescribed types of antidepressants include selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). For such medications, limited adverse effects and reasonable tolerability are critically important in addition to the efficacy in treating depression and their affordability. In this study, I quantitatively assessed the adverse events reported in the comprehensive FAERS (FDA Adverse Event Reporting System) database in terms of case count by received year, by age group, by sex, by reaction type, and by outcome, with respect to those commonly used antidepressants. Although the total count of adverse events increases every year before 2019, my analysis shows an alarming decrease in total count over the COVID pandemic period (2020 & 2021) while the number of people with depression rose significantly because of the pandemic. “Completed suicide” turns out to be one of the main side reactions reported across all anti-depression medications. Statistical analysis demonstrated that the reported number of “completed suicide” correlates with the report number of “suicide attempt” (or “suicidal ideation”). Surprisingly, the reported case count by females is significantly larger than that by males regardless of the grouping approach. It was evident that such insights could provide meaningful guidance on strengthening mental health systems for COVID-19 & future public health emergencies and further support relevant scientific studies on adverse effects & tolerability of effective antidepressant medications.

show abstract

Other Antidepressants

Cited by 6 publications

References 202 publications

Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression

Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression

Synthesis of anti-depressant molecules via metal-catalyzed reactions: a review

Assessment of Reported Adverse Events on Anti-Depressants

Contact Info

Product

Resources

About